BLACKROCK HEALTH SCIENCES (BME) Stock Overview
USA - NYSE:BME - US09250W1071
38.3 USD
+0.16 (+0.42%)
Taking everything into account, BME scores 2 out of 10 in our fundamental rating. BME was compared to 0 industry peers in the Unkown industry. BME has a bad profitability rating. Also its financial health evaluation is rather negative. BME does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
BME had negative earnings in the past year.
In the past year BME had a positive cash flow from operations.
BME had positive earnings in 4 of the past 5 years.
In multiple years BME reported negative operating cash flow during the last 5 years.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.83% | ||
| ROE | -5.03% | ||
| ROIC | 0.16% |
ROA(3y)1.06%
ROA(5y)5.33%
ROE(3y)1.07%
ROE(5y)5.44%
ROIC(3y)0.2%
ROIC(5y)0.12%
1.3 Margins
BME's Profit Margin has declined in the last couple of years.
BME's Operating Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.92% | ||
| PM (TTM) | N/A | ||
| GM | 100% |
OM growth 3Y169.88%
OM growth 5Y-0.74%
PM growth 3Y-30.97%
PM growth 5Y-28.42%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BME has less shares outstanding than it did 1 year ago.
The number of shares outstanding for BME has been increased compared to 5 years ago.
The debt/assets ratio for BME is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 14.44 indicates that BME is not in any danger for bankruptcy at the moment.
The Debt to FCF ratio of BME is 0.02, which is an excellent value as it means it would take BME, only 0.02 years of fcf income to pay off all of its debts.
A Debt/Equity ratio of 0.00 indicates that BME is not too dependend on debt financing.
Although BME does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.02 | ||
| Altman-Z | 14.44 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
BME has a Current Ratio of 0.10. This is a bad value and indicates that BME is not financially healthy enough and could expect problems in meeting its short term obligations.
BME has a Quick Ratio of 0.10. This is a bad value and indicates that BME is not financially healthy enough and could expect problems in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.1 | ||
| Quick Ratio | 0.1 |
3. Growth
3.1 Past
The earnings per share for BME have decreased strongly by -150.26% in the last year.
Measured over the past years, BME shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.80% on average per year.
BME shows a decrease in Revenue. In the last year, the revenue decreased by -6.58%.
BME shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.91% yearly.
EPS 1Y (TTM)-150.26%
EPS 3Y-26.89%
EPS 5Y-24.8%
EPS Q2Q%-108.48%
Revenue 1Y (TTM)-6.58%
Revenue growth 3Y5.76%
Revenue growth 5Y8.91%
Sales Q2Q%-2.46%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
BME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.03 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
BME has a Yearly Dividend Yield of 7.65%, which is a nice return.
Compared to an average S&P500 Dividend Yield of 2.34, BME pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 7.65% |
5.2 History
The dividend of BME has a limited annual growth rate of 3.39%.
BME has been paying a dividend for at least 10 years, so it has a reliable track record.
BME has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)3.39%
Div Incr Years1
Div Non Decr Years10
5.3 Sustainability
The earnings of BME are negative and hence is the payout ratio. BME will probably not be able to sustain this dividend level.
DP-148.67%
EPS Next 2YN/A
EPS Next 3YN/A
NYSE:BME (10/24/2025, 3:43:45 PM)
38.3
+0.16 (+0.42%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)
Earnings (Next)
Inst Owners23.81%
Inst Owner Change-0.01%
Ins Owners0%
Ins Owner Change0%
Market Cap494.84M
Revenue(TTM)7.47M
Net Income(TTM)-25560000
Analysts0
Price TargetN/A
Short Float %0.14%
Short Ratio0.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 7.65% |
Yearly Dividend2.67
Dividend Growth(5Y)3.39%
DP-148.67%
Div Incr Years1
Div Non Decr Years10
Ex-Date
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 66.24 | ||
| P/FCF | 6.03 | ||
| P/OCF | 6.03 | ||
| P/B | 0.97 | ||
| P/tB | 0.97 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.97
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)6.35
FCFY16.57%
OCF(TTM)6.35
OCFY16.57%
SpS0.58
BVpS39.32
TBVpS39.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.83% | ||
| ROE | -5.03% | ||
| ROCE | 0.2% | ||
| ROIC | 0.16% | ||
| ROICexc | 0.16% | ||
| ROICexgc | 0.16% | ||
| OM | 13.92% | ||
| PM (TTM) | N/A | ||
| GM | 100% | ||
| FCFM | 1097.72% |
ROA(3y)1.06%
ROA(5y)5.33%
ROE(3y)1.07%
ROE(5y)5.44%
ROIC(3y)0.2%
ROIC(5y)0.12%
ROICexc(3y)0.2%
ROICexc(5y)0.12%
ROICexgc(3y)0.2%
ROICexgc(5y)0.12%
ROCE(3y)0.25%
ROCE(5y)0.16%
ROICexgc growth 3Y199.74%
ROICexgc growth 5Y4.01%
ROICexc growth 3Y199.74%
ROICexc growth 5Y4.01%
OM growth 3Y169.88%
OM growth 5Y-0.74%
PM growth 3Y-30.97%
PM growth 5Y-28.42%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.02 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.1 | ||
| Quick Ratio | 0.1 | ||
| Altman-Z | 14.44 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-150.26%
EPS 3Y-26.89%
EPS 5Y-24.8%
EPS Q2Q%-108.48%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.58%
Revenue growth 3Y5.76%
Revenue growth 5Y8.91%
Sales Q2Q%-2.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-38.46%
EBIT growth 3Y185.41%
EBIT growth 5Y8.1%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y432.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y432.12%
OCF growth 3YN/A
OCF growth 5YN/A
BLACKROCK HEALTH SCIENCES / BME FAQ
What does BME do?
Blackrock Health Sciences Trust is a US-based company operating in industry. The company is headquartered in Wilmington, Delaware. The company went IPO on 2005-03-29. BlackRock Health Sciences Trust (the Trust) is a closed-end management investment company. The Trust investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and by employing a strategy of writing (selling) call and put options. The Trust invests in a portfolio of sectors, which include pharma, biotech and life sciences; healthcare equipment and services; semiconductors & semiconductor equipment; financial services, and others. BlackRock Advisors, LLC acts as the investment adviser of the Trust.
What is the stock price of BLACKROCK HEALTH SCIENCES today?
The current stock price of BME is 38.3 USD. The price increased by 0.42% in the last trading session.
What is the ChartMill rating of BLACKROCK HEALTH SCIENCES stock?
BME has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.